Clinical Trial Update: Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of Sym004 in metastatic colorectal cancer and ECD-EGFR patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Sym004

Snippet

Sponsor: Symphogen A/S | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: WITHDRAWN